Just to bring everyone up to speed I will start with an anlogy. Think of your body as a house that’s been lived in for decades. Most cells are like light bulbs: when they burn out, they’re supposed to switch off and get replaced. Senescent cells are bulbs that are broken, won’t turn off, and keep flickering, sending electrical noise through the system. They don’t help anymore, but they keep drawing power and overheating the wiring around them. These senescent cells survive because they’ve learned a trick. They turn on powerful “do not shut down” systems that block the body’s normal cleanup process. At the same time, they release inflammatory signals like a stuck fire alarm that stress nearby cells and push them toward the same broken state. Over time, this creates chronic inflammation, slower healing, tissue stiffness, and many features we associate with aging. Fisetin works by cutting the backup power to those broken bulbs. It doesn’t smash healthy cells. Instead, it targets the special survival systems that senescent cells rely on to avoid self-destruction. Once those systems are disabled, the senescent cell can finally shut itself down and be cleared away by the body. This is why fisetin is called a senolytic it helps remove cells that should have exited but didn’t. At the same time, fisetin turns down the inflammatory “noise.” It dampens the internal alarm system that senescent cells use to broadcast stress signals. Even if a senescent cell isn’t removed immediately, it becomes quieter and less damaging to its surroundings. This helps prevent the spread of dysfunction to neighboring cells. Fisetin also nudges the cell’s energy and stress controls back toward balance. You can think of this like switching a building from constant emergency mode back to maintenance mode. Growth and survival signals that favor damaged cells are reduced, while cleanup and recycling processes are supported. This makes it harder for dysfunctional cells to hang on and easier for healthy tissue to recover.

@Toby Horon I would think about these as three different tools, not three versions of the same tool. A senescent cell is basically a cell that stopped doing its job, but did not leave the building. It is not fully dead, but it is not functioning normally either. Worse, it can send out inflammatory signals that disturb the cells around it. That is why people call them “zombie cells.” If the goal is specifically to clear senescent cells, FOXO4-DRI is the most targeted option mechanistically, but only in the right hands. This is not something I would treat like a casual longevity supplement. FOXO4-DRI works by interfering with the FOXO4-p53 interaction. Think of p53 as one of the cell’s quality-control managers. It helps decide whether a damaged cell should repair, pause, or self-destruct. Some senescent cells use FOXO4 to keep p53 from pushing them into apoptosis, which is programmed cell death. FOXO4-DRI helps remove that protection, so the damaged cell is more likely to be cleared. That is why it is interesting. It is also why I would want guardrails. People can feel pretty flu-like with it, likely because clearing inflammatory cells can create a temporary cleanup response. The immune system has to process debris, inflammatory signals can shift, and the body can feel like it is doing work. So with FOXO4-DRI, I would want a qualified professional, a clear reason, timing, recovery support, hydration, training adjustments, and endpoints. Fisetin is the more approachable starting point. It is not as targeted as FOXO4-DRI, but it may influence several pathways involved in senescence and inflammation. These include NF-kB, PI3K-AKT, mTOR-related signaling, oxidative stress pathways, and SASP signaling. In plain English, fisetin is not acting like a sniper. It is more like changing the environment so old inflammatory cells have a harder time hanging around and making noise. It may help turn down some of the inflammatory messaging that senescent cells produce. That makes fisetin more practical for many people. Lower barrier. Lower complexity. Easier to implement. But I would still not call it a guaranteed “zombie cell cleanse.” The 3-day fast is a different category. Fasting can lower insulin, lower mTOR, raise AMPK, increase ketones, and increase autophagy. Those are real effects. But that does not automatically make fasting a direct senolytic. The simple way to think about it is this. FOXO4-DRI is trying to remove specific damaged cells. Fisetin may help make the environment less friendly to those cells. Fasting mostly changes the whole terrain. That terrain shift can be useful, but it is not the same as directly targeting senescent cell survival pathways. I would also be careful with the “stem cell release” claim. Most of the stronger data around prolonged fasting and stem-cell regeneration comes from animal models, immune-system regeneration research, and chemotherapy-related settings. That is very different from saying a healthy adult does an 84-hour fast and gets a broad full-body stem-cell surge. Same with insulin sensitivity. Fasting may help most in people with excess body fat, insulin resistance, metabolic dysfunction, or type 2 diabetes. But in a healthy, active person, there are usually better ways to pull those same levers. Better food quality, meal timing, strategic carbohydrates, adequate protein, resistance training, Zone 2 work, sleep, and controlled energy balance can all improve insulin sensitivity and metabolic flexibility without removing nutrients for three days. That matters because fasting does not just remove calories. It also removes incoming amino acids, minerals, vitamins, and cofactors the body uses for detoxification, glutathione production, mitochondrial energy, redox balance, hormone signaling, and repair. Detoxification is not magic. It is chemistry. Chemistry needs raw materials. So while a 3-day fast can increase certain cleanup signals, it can also temporarily deprive the body of the nutrients needed to run cleanup, energy production, and recovery well. In some people it can also disrupt sleep, training quality, thyroid output, cortisol rhythm, mood, and recovery. So my hierarchy would be simple. FOXO4-DRI if the goal is targeted senolytic work, but only with a qualified professional and a real plan. Fisetin as the more approachable, lower-friction starting point. A 3-day fast as a broad metabolic stress tool, not my preferred choice for senescent cell clearance in a healthy adult.

@Derek Davis That’s a really good question, and the fact that you’re looking at patterns instead of just single numbers already puts you in a strong position. HRV is not just a recovery score, it’s a reflection of how well your nervous system is adapting to stress. Under the surface, that ties directly into mitochondrial energy production, redox balance, immune activity, and your ability to shift between sympathetic and parasympathetic states. The pattern you described matters more than the actual number. You have a baseline HRV around 40 to 45, it drops into the low 30s after something like evening Jiu-Jitsu or when you’re sick, and then it comes back up to baseline. That is not a sign of dysfunction. That is exactly what a healthy, responsive system should do. A simple way to think about it is like a high-performance suspension system. When you hit stress, the system compresses. When the stress is removed, it rebounds back to baseline. If your HRV drops after hard training or illness, it means your body is recognizing the stress and reallocating resources where they are needed, increasing sympathetic tone, activating the immune system, and directing energy toward repair. That is the correct response. The role of redox balance here is in how efficiently you handle that stress and how quickly you return to baseline. The real question is not whether HRV drops, it’s how fast and how cleanly it recovers. Based on what you described, you are able to mount a stress response and then recover from it. That suggests your mitochondrial signaling, redox buffering capacity, and autonomic flexibility are all functioning well. In simple terms, your system bends but it does not stay bent. It would be more concerning if your HRV stayed suppressed for multiple days without a clear reason, if your baseline gradually trended downward over time, or if you felt off even when HRV looked normal. Those patterns can point toward redox imbalance, mitochondrial inefficiency, or chronic stress that the system is not resolving.

@Eric Keester It’s very possible that what you’re describing is a redox environment that isn’t fully restoring baseline, which can create that constant pull toward things like sunlight, red light, grounding, or cold. Those inputs all improve electron flow, mitochondrial signaling, and autonomic balance, so when someone feels like they “need” them all the time, it can be a sign the system is leaning on external inputs to stabilize rather than holding steady on its own. That doesn’t mean something is broken, it usually means the system is under more load than it can fully resolve, or it hasn’t rebuilt enough capacity yet. A helpful way to think about it is that those tools are like charging stations. Using them is beneficial, but if you feel like you constantly need to plug in just to feel normal, that suggests your baseline charge is not being maintained efficiently. That can come from training load, circadian disruption, immune activity, or just cumulative stress that hasn’t fully cleared. On the DSIP and Epithalon piece, the drop in HRV doesn’t automatically mean something is wrong, but it is a signal worth paying attention to. Both of those compounds can shift neurochemistry and circadian signaling in ways that don’t always show up as a simple increase in HRV right away. DSIP in particular can deepen sleep pressure and alter GABAergic tone, and Epithalon is influencing circadian rhythm and melatonin pathways. In some people, especially early on, that can actually show up as a temporary reduction in HRV because the system is reorganizing rather than just relaxing. Another angle is that if sleep becomes deeper or more “recovery focused,” HRV can paradoxically look lower while the body is doing more internal work. HRV is not a direct measure of sleep quality, it is a measure of autonomic balance, so if the body is allocating more resources toward repair, immune activity, or recalibration, HRV can dip even though the process is beneficial.

@Josh Blair That’s a really good observation and you’re thinking about the right interaction, which is the relationship between substrate availability, signaling pathways, and the specific adaptation you’re trying to drive. The concern around using trehalose near hypertrophy training comes from the idea that anything pushing toward autophagy or cellular cleanup could theoretically compete with mTOR signaling, which is what you want dominant for growth. In practice, trehalose is a relatively mild signal compared to something like fasting, ketones, or strong AMPK activation, so the interference is not as dramatic as people assume. That said, when the goal is maximizing hypertrophy, it still makes sense to be intentional with timing. Where I tend to use trehalose is when the goal of the session is more aligned with mitochondrial stress, metabolic flexibility, or aerobic development. In those cases, you actually want a bit more of that cellular cleanup and efficiency signaling, so using trehalose before or around those sessions can make sense. For hypertrophy-focused sessions, I generally would not prioritize trehalose pre or intra workout. I would lean more toward supporting performance, mechanical tension, and recovery through adequate amino acids, electrolytes, and carbohydrates that are clearly directed toward fueling the session and supporting mTOR signaling. If trehalose is used on those days, it is usually better placed away from the training window, either earlier in the day or later, so you are not blunting the primary signal you are trying to create. For conditioning or lower intensity aerobic work, using something like five grams of trehalose pre workout can be reasonable. It provides a mild substrate while also nudging some of the proteostasis and autophagy pathways in a direction that supports long term mitochondrial health. So the simple way to think about it is this. When the goal is growth, keep the environment biased toward building. When the goal is efficiency, resilience, and cleanup, that is where trehalose becomes more useful around the training window.

@Josh Blair Yes, if the goal is simply to raise blood glucose and insulin around training, dextrose is sufficient. That said, if you want a simple option that does a little more than just provide glucose, honey is a great choice. Honey gives you glucose plus fructose, which can improve total carbohydrate handling because they use partly different intestinal transporters. In plain English, that can make it easier to take in carbs without as much gut stress. Honey also brings small amounts of enzymes, polyphenols, and trace minerals that dextrose does not. It is still primarily a sugar source, but it is a more biologically “complete” one. Dextrose is still absolutely fine. It is cheap, simple, fast, and predictable. If someone wants a very clean pre, intra, or post-workout carb source with rapid absorption and no extra variables, dextrose does the job well. Highly branched cyclic dextrin is a little different. Its main advantage is usually gastric comfort. It tends to empty from the stomach quickly while still giving a steady carbohydrate delivery, so it is often a better choice during training, especially for longer sessions or for people who get bloated or nauseous from simpler sugars. Best use case is intra-workout, high-volume sessions, hard conditioning, or athletes who need carbs but want the least GI disruption. Vitargo is another specialized carb. It is known for rapid gastric emptying and strong glycogen-repletion potential, so it can be very useful when fast recovery matters, especially if you are training again soon or doing very glycogen-depleting work. Best use case is immediately after hard training or between two sessions in the same day. Some people also do well with it peri-workout, but it tends to shine most when recovery speed is the priority. A simple way to think about it is this: Honey is great when you want a natural mixed sugar source that is easy to use and often easier on the gut than straight dextrose.

There is a lot more nuance here than most social media discussions make it sound. First, I am not a physician and I am definitely not an oncologist, so this is above my pay grade in terms of making a cancer-risk decision for any individual. That kind of decision should be made with a physician who knows the person’s history, risk factors, active diagnoses, imaging, and family history. Mechanistically, the biggest mistake people make is collapsing three very different concepts into one bucket. One is endogenous overexpression of a molecule inside a tumor or tumor microenvironment. Two is short term exogenous therapeutic exposure. Three is broad pathway involvement, like saying “VEGF is involved.” Those are not interchangeable. A pathway being involved in wound healing and also involved in cancer biology does not mean every intervention that touches that pathway is therefore oncogenic. VEGF is a normal physiologic wound-healing signal, and angiogenesis is a normal part of repair. In fact, anti-VEGF therapy can impair wound healing, which tells you immediately that VEGF is not inherently “bad,” it is context-dependent. That is where the distinction between modulation and stimulation matters. “Stimulation” implies pushing a pathway in a more blunt, sustained, or generalized way. “Modulation” implies altering signaling in a context-sensitive manner, often interacting with an already injured or dysregulated tissue state. The BPC-157 literature, limited as it is, tends to describe effects more in the direction of endothelial protection, VEGFR2-Akt-eNOS signaling, nitric oxide regulation, and repair-associated angiogenesis rather than proof of autonomous oncogenic transformation. In other words, the signal appears more like “help the damaged tissue organize repair” than “create a tumor from scratch.” But that is not the same as saying it is proven cancer-safe in all settings, because it is not. On the BPC side specifically, the usual VEGF argument is directionally incomplete. Yes, BPC-157 has preclinical data suggesting pro-angiogenic effects and involvement of VEGFR2 and eNOS signaling. But angiogenesis in repair is not the same thing as malignant angiogenesis. Tumor angiogenesis usually exists inside a much larger disease program involving oncogenic mutations, hypoxia signaling, inflammatory cytokines, immune evasion, extracellular matrix remodeling, and a permissive tumor microenvironment. VEGF can support that process, but VEGF alone is generally not treated as a sole root cause of cancer initiation. It is better understood as a growth-supporting and vessel-remodeling mediator in an already permissive environment. That is why saying “BPC touches VEGF, therefore BPC causes cancer” is a major oversimplification.